China has approved the use of an experimental coronavirus vaccine for members of the country’s military, the South China Morning Post reported on Tuesday.
The vaccine, known as Ad5-nCoV, was reportedly developed by a team from the Academy of Military Medical Sciences and Tianjin-based pharmaceutical company CanSino Biologics. In a statement Monday, CanSino announced that the vaccine candidate had successfully passed two phases of clinical trials indicating it was safe to use and would provide a “relatively high” immune response to the coronavirus antigen.
The essential phase three trials are yet to take place, which will confirm if the vaccine can successfully prevent infection. Phases one and two typically indicate whether the vaccine is safe for use without any unwarranted side effects, although all candidates must complete phase three to obtain and license to go on sale.
According to Major General Chen Wei, who led the vaccine’s development, the vaccine is based on a similar